z-logo
open-access-imgOpen Access
Air travel and thrombosis
Author(s) -
F.R. Rosendaal
Publication year - 2002
Publication title -
pathophysiology of haemostasis and thrombosis
Language(s) - English
Resource type - Journals
eISSN - 1424-8840
pISSN - 1424-8832
DOI - 10.1159/000073594
Subject(s) - medicine , asymptomatic , pulmonary embolism , thrombosis , deep vein , venous thrombosis , risk factor , surgery
Although the first cases of thrombosis following air travel were reported in 1954 by Homans (1), interest has recently heightened. Numerous cases have been reported, but con- trolled studies are few and contradictory. In a series of patients who had died suddenly at Heathrow Airport, this occurred far more often in the arrival than in the departure area (2). Case- control studies have yielded conflicting results, with two French studies showing a two to fourfold increased risk of travel compared to no travel (3;4), while a Dutch (5) and a British study (6) found no elevated risk. A study of severe pul- monary embolism in travellers showed a 50-fold risk gradient with the distance travelled (7), while two studies using ultra- sound measurements to detect asymptomatic clots found these in a significant number of travellers (8;9). The Multiple Environmental and Genetic Assessment (MEGA) is an ongoing case-control study aimed at assessing interactive effects of genetic and acquired risk factors for venous thrombosis. Cases are consecutive patients with a first objectively confirmed deep-vein thrombosis (DVT) or pul- monary embolism (PE) registered for anticoagulant treatment at six regional Anticoagulation Clinics. Controls are spouses of of cases. There are no exclusion criteria. Cases and controls fill out a detailed questionnaire, are interviewed in-person, and have venous blood drawn. For the current report, we have data on 829 cases and 829 controls. We considered as travel, any travel of more than 4 hours in two months preceeding the index data. Factor V Leiden (FVL) and prothrombin 20210A (PT20210A) were measured by standard PCR techniques. 465 (56%) patients had DVT, 341 PE (41%). A prothrom- botic mutation (FVL or PT20201A) was present in 19.9% of patients and 7.7% of controls (OR=2.9, CI95 1.9-4.3). 112 (13.5%) of patients had travelled in the preceeding two months, for 30 of whom thrombosis was diagnosed within one week after travel. For all modes of travel combined, it increased risk of thrombosis 3-fold (OR=3.1, CI95 1.9-5.1). Plane travel increased risk 6-fold (OR=5.8, CI95 2.0-16.6) and other modes of travel 2-fold (OR 2.2, CI95 1.9-4.3). Individuals with a prothrombotic mutation who travelled by airplane had a 13-fold increased risk compared to individuals without a mutation who did not travel. This joint risk exceed- ed the sum of the separate risks of flying and mutations. Prolonged travel by car, autobus and airplane is associated with an increased risk of venous thrombosis, with the highest risk for air travel. Individuals with prothrombotic mutations are at higher risk.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom